Table 1 Demographic and clinicopathological characteristics of 1239 IgAN patients and 497 patients matched by propensity score
From: Cigarette smoking may accelerate the progression of IgA nephropathy
Characteristics | Before PSM | After PSM | ||
|---|---|---|---|---|
Non-smokers (1030) | Smokers (209) | Non-smokers (318) | Smokers (179) | |
Clinical | ||||
Male (%) | 351 (34.1) | 203 (97.1) ** | 299 (94) | 173 (96.6) |
Hypertension (%) | 252 (24.5) | 79 (37.8) ** | 98 (30.8) | 64 (35.8) |
SBP (mmHg) | 127.0 ± 18.2 | 127.6 ± 16.5 | 129.2 ± 17.4 | 128.2 ± 16.2 |
DBP (mmHg) | 83.0 ± 13.2 | 83.0 ± 13.4 | 84.9 ± 12.8 | 83.7 ± 13.1 |
Serum creatinine (umol/L) | 88.3 ± 41.3 | 116.6 ± 54.2 ** | 108.5 ± 49.3 | 115.8 ± 55.3 |
eGFR (mL/min per 1.73m2) | 93.8 ± 31.3 | 82.8 ± 33.7 ** | 90.7 ± 32.3 | 85.0 ± 34.3 |
Urine protein (g/24 h) | 2.1 ± 2.5 | 2.7 ± 3.0 ** | 2.3 ± 2.7 | 2.4 ± 2.6 |
Treatment | ||||
Support treatment (%) | 436 (42.3) | 77 (36.8) | 145 (45.6) | 68 (38) |
Prednisone or other immunosuppressive agents (%) | 594 (57.7) | 132 (63.2) | 173 (54.4) | 111 (62) |
Pathologic | Oxford Classification | |||
M1 (%) | 774 (75.2) | 116 (77) | 243 (76.4) | 137 (76.5) |
E1 (%) | 47 (4.6) | 12 (5.7) | 9 (2.8) | 9 (5) |
S1 (%) | 623 (60.5) | 130 (62.2) | 189 (59.4) | 115 (64.2) |
T1/T2 (%) | 179 (17.4) | 58 (27.8) ** | 79 (24.8) | 51 (28.5) |
C1/C2 (%) | 239 (23.2) | 49 (23.4) | 77 (24.2) | 38 (21.2) |